Navigation Links
New transdermal SARM drug for muscle-wasting offers hope for older cancer patients
Date:6/24/2014

CHICAGO, ILMuscle wasting that occurs as a result of cancer negatively impacts the well-being and recovery prospects of millions of patients, particularly the rapidly-growing elderly populations in Western societies. Drugs called selective androgen receptor modulators (SARMs) offer hope for these patients, and a new SARM for transdermal administration is promising excellent efficacy without harming liver function and HDL levels. Results and conclusions were presented Tuesday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

SARMs are able to stimulate the growth of muscle with effects similar to those seen by use of traditional anabolic steroids but without the undesirable side effects of those established muscle-building drugs, in particular, the adverse effects on prostate health that can occur from their use.

There are several SARMs currently in human clinical trials, with successful animal studies having already been conducted with these compounds. However, all of these drug candidates have been developed for oral administration. Because of potential adverse effects on liver function and on depression of HDL levels (the "good" cholesterol), the orally-administered drugs suffer limitations to their full therapeutic potential to grow muscle and strengthen bone.

A similar situation for oral delivery exists in the administration of male hormone therapy. Here, the adverse impacts on liver health and HDL levels can be overcome by the use of skin patches or gel that release a drug directly into the body through the skin, i.e., transdermal application. Recognizing the similarity, scientists at the pharmaceutical company Novartis therefore developed a SARM specifically for transdermal administration. In describing their drug candidate, AUSRM-057, Senior Investigator Dr. Hans-Joerg Keller of the Novartis Institutes for BioMedical Research, Basel, Switzerland said, "AUSR
'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New study offers potential avenues for treatment of deadly nasopharyngeal cancer
2. Study offers evidence that sunscreen use in childhood prevents melanoma in adults
3. New report offers a primer for doctors use of clinical genome and exome sequencing
4. Liquid biopsy offers new way to track lung cancer
5. Molecule linked to aggressive pancreatic cancer offers potential clinical advances
6. NIDA offers tools for talking to teens about marijuana
7. Extended-release medication offers promise for treating alcohol, opioid dependence
8. Mouse study offers new clues to cognitive decline
9. Breath analysis offers non-invasive method to detect early lung cancer
10. Review offers insight on managing surgical patients who are taking new drugs to prevent blood clots
11. New high-detail atlas offers tool to explore local environment and health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... in the U.S. are living with a brain tumor, ... risk factors, scientists are still searching for answers. , ... when, and we don,t know why people develop brain ... American Brain Tumor Association. "It,s frustrating for the brain ... Association funds research to pursue answers to these questions, ...
(Date:7/25/2014)... CMS recently has imposed a series ... inadequate access to prescription drugs. Agency audits are uncovering ... safety of beneficiaries in areas such as rejected pharmacy ... is taking quick and firm actions to halt them. ... “Avoiding Costly Part D Sanctions: Rx Access Strategies ...
(Date:7/25/2014)... Fort Myers, FL (PRWEB) July 25, 2014 ... Apple iPhones, iPods, and iPads. The app provides a ... preventing painful and potentially dangerous sunburns and skin damage. ... about the sights, sounds, and capabilities of iTanSmart. ... by describing the app as a ‘better organized’ and ...
(Date:7/25/2014)... July 25, 2014 As the category creator ... Xoçai is to transform and improve individual lives ... Adam Paul Green a successful Austin, Texas based ... at the end of the July to promote the up ... September 2014. , Eric Worre has been a leader in ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
Breaking Medicine News(10 mins):Health News:Brain tumor causes and risk factors elude scientists 2Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... Companies Will Discuss Recent FDA Advisory Regarding Byetta, ... LLY ) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 2008 at 5:00 p.m. EDT to discuss the,recent FDA ... Lilly will be Donald Therasse, M.D., vice president of ...
... they spend billions out of pocket for what they do ... -- Uninsured Americans will spend $30 billion out of pocket ... in 2008, new research shows. , Uncompensated care is ... for by the uninsured or a health insurer. , In ...
... center for Tuesday, August 26, between 2:00 - 2:30 ... abortion., Two Catholic Priests, one Evangelical Pastor among ... Rescue Founder says:, "Obama,s pick of Biden is ... betrayal of his Faith will help mobilize Catholic,clergy and ...
... say bloodletting is the best available option for people ... -- Bloodletting is often dismissed as a primitive form ... the body of bad humors by draining the life-sustaining ... where bloodletting is still the preferred means of treatment. ...
... 25 Borrowing and sharing of,prescription medications is ... of nearly 7,500 women of reproductive age found ... of this population, according to a,report published online ... a,peer-reviewed journal published by Mary Ann Liebert, Inc. ...
... The U.S. Pharmacopeial (USP) Convention today announces a new ... physicians and others in avoiding medication errors that may ... sound alike. This "Drug Error Finder" is a searchable ... be involved in medication mix-ups in the U.S. health ...
Cached Medicine News:Health News:Lilly and Amylin Set Date and Time for Conference Call 2Health News:Uninsured Get Less Health Care Than Insured 2Health News:DNC 'Party Crashers:' Police Arrest 1 Pro-lifer at Black Caucus; Eject Operation Rescue Leader from DNC Interfaith Gathering at Colorado Convention Center 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:Trends in Prescription Medication Sharing Among Reproductive-Aged Women Reported in Journal of Women's Health 2Health News:USP announces new tool to help prevent medication mix-ups due to look alike/sound alike drug names 2
(Date:7/24/2014)... July 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... on the development and commercialization of innovative therapies for ... the PDUFA date for Zalviso remains July 27, 2014.  ... circulated online stating the Food and Drug Administration (FDA) ... has been no notification to the company from the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Pa., April 23 Wyeth,Pharmaceuticals, a division of ... it,is withdrawing its application for an extension to ... sought approval,of TYGACIL for the treatment of community-acquired ... of the Committee for Medicinal,Products for Human Use ...
... an Investigational Drug for Duchenne/Becker ... Muscular Dystrophy, ... announced the initiation of an international pivotal trial of,PTC124 in patients ... objective of this registration-directed,Phase 2b trial is to demonstrate the efficacy ...
Cached Medicine Technology:More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 2More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 3More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 4More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 5PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 5
Shielding's Wrap-Around Apron is designed for front and back protection. This apron features extra wide shoulders distributing weight over a greater area to reduce fatigue....
Shielding's Velcro Adjustable Apron has two velcro flaps which aid in relieving weight off the shoulders. Its comfortable fit is attained by varying the position of flaps....
Upper arm protection...
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
Medicine Products: